Literature DB >> 10540041

Review article: nonsteroidal anti-inflammatory drug-associated gastrointestinal complications--guidelines for prevention and treatment.

P Schoenfeld1, M B Kimmey, J Scheiman, D Bjorkman, L Laine.   

Abstract

Chronic ingestion of NSAIDs increases the risk for gastrointestinal complications, which range from dyspepsia to gastrointestinal bleeding, obstruction, and perforation. Among patients using NSAIDs, 0.1 to 2.0% per year suffer serious gastrointestinal complications. Patients who require analgesic therapy should be carefully assessed for the lowest possible dosage and shortest duration of NSAID use and for the potential of treatment with a non-NSAID pain reliever. These patients should also be assessed for factors that increase their risk of gastrointestinal complications, including increased age, concomitant anticoagulant or corticosteroid use, and past history of NSAID-associated gastrointestinal complications. The exact association between Helicobacter pylori infection and NSAID-related ulcer disease is unclear, and the routine testing and treatment of all NSAID using patients for H. pylori infection is not recommended at this time. NSAID-using patients who suffer from dyspepsia should have NSAIDs discontinued, the dosage changed, or be changed to a different class of NSAID. If NSAIDs cannot be discontinued, then an antisecretory agent should be initiated. Misoprostol prevents NSAID-associated gastrointestinal complications. Proton pump inhibitors are the most effective at healing NSAID-associated ulcers among patients who cannot discontinue NSAID therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10540041     DOI: 10.1046/j.1365-2036.1999.00617.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  25 in total

1.  Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database.

Authors:  François Clinard; Catherine Sgro; Marc Bardou; Patrick Hillon; Monique Dumas; Carmen Kreft-Jais; André Escousse; Claire Bonithon-Kopp
Journal:  Eur J Clin Pharmacol       Date:  2004-04-22       Impact factor: 2.953

2.  Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury.

Authors:  Tatsushi Omatsu; Yuji Naito; Osamu Handa; Katsura Mizushima; Natsuko Hayashi; Ying Qin; Akihito Harusato; Ikuhiro Hirata; Etsuko Kishimoto; Hitomi Okada; Kazuhiko Uchiyama; Takeshi Ishikawa; Tomohisa Takagi; Nobuaki Yagi; Satoshi Kokura; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  J Gastroenterol       Date:  2010-02-20       Impact factor: 7.527

3.  Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study.

Authors:  Viktorija Erdeljic; Igor Francetic; Viola Macolic Sarinic; Marinko Bilusic; Ksenija Makar Ausperger; Mirjana Huic; Iveta Mercep
Journal:  Pharm World Sci       Date:  2006-11-17

4.  Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid.

Authors:  Martijn G H van Oijen; Sylvie Huybers; Wilbert H M Peters; Joost P H Drenth; Robert J F Laheij; Freek W A Verheugt; Jan B M J Jansen
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 5.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern.

Authors:  Louise Barnard; Dominic Lavoie; Nancy Lajeunesse
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 7.  Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements.

Authors:  Merel M Tielemans; Ties Eikendal; Jan B M J Jansen; Martijn G H van Oijen
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

8.  Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugs.

Authors:  L Gallelli; M Colosimo; D Pirritano; M Ferraro; S De Fazio; N M Marigliano; G De Sarro
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models.

Authors:  Cameron S Metcalf; Brian D Klein; Daniel R McDougle; Liuyin Zhang; Misty D Smith; Grzegorz Bulaj; H Steve White
Journal:  J Pharmacol Exp Ther       Date:  2014-10-27       Impact factor: 4.030

10.  Mechanisms underlying the anti-inflammatory activity and gastric safety of acemetacin.

Authors:  A E Chávez-Piña; W McKnight; M Dicay; G Castañeda-Hernández; J L Wallace
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.